"10.1371_journal.pone.0050401","plos one","2012-11-30T00:00:00Z","Nirmala Mavila; David James; Sarah Utley; Nguyen Cu; Orly Coblens; Katrina Mak; C Bart Rountree; Michael Kahn; Kasper S Wang","Saban Research Institute, Childrens Hospital Los Angeles, Los Angeles, California, United States of America; Department of Biochemistry and Molecular Biology and Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America; Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America; Pediatric Gastroenterology, Bon Secours St. Marys Hospital, Richmond, Virginia, United States of America","Conceived and designed the experiments: NM SU NC CBR MK KW. Performed the experiments: NM DJ SU NC OC KM. Analyzed the data: NM DJ SU NC CBR MK KW. Contributed reagents/materials/analysis tools: NM DJ SU NC CBR MK KW. Wrote the paper: NM KW.","MK owns equity in Prism Pharmaceuticals which is developing a CBP/Î²-catenin antagonist. Other authors have nothing to report. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","11","Nirmala Mavila","NM",9,TRUE,6,6,7,2,TRUE,TRUE,FALSE,0,NA,FALSE
